argus

Biocon Ltd.

NSE: BIOCONINE376G0101365,391 Cr

Timeline

Time (IST)TypeMEventSrc
06 Dec, 10:16 amBiocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
06 Dec, 10:14 amBiocon Limited has informed the Exchange regarding Outcome of Board Meeting held on December 06, 2025.nse
06 Dec, 10:12 amBiocon Ltd - 532523 - Board Meeting Outcome for Outcome Of Board Meeting Under Regulation 30 Of SEBI Listing Regulations, 2015bse
05 Dec, 06:05 pmBiocon Limited has informed the Exchange regarding 'Notification to Stock Exchanges'.nse
03 Dec, 10:53 pmBiocon Ltd - 532523 - Board Meeting Intimation for Intimation Of Board Meetingbse
02 Dec, 09:10 amBiocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
02 Dec, 09:04 amBiocon Limited has informed the Exchange regarding a press release dated December 02, 2025, titled "Biocon Biologics Secures Market Entry Date for Denosumab Biosimilars in Europe and Rest of the World®".nse
27 Nov, 08:23 amBiocon Limited has informed the Exchange regarding 'Company Statement'.nse
19 Nov, 09:07 amBiocon Limited has informed the Exchange about Notification to Stock Exchangesnse
18 Nov, 05:14 pmBiocon Ltd - 532523 - Transcript Of Earnings Call Q2 FY26bse
18 Nov, 04:58 pmBiocon Limited has informed the Exchange about Transcriptnse
14 Nov, 08:30 amBiocon Limited has informed the Exchange about Rumour Verification - Regulation 30(11)nse
13 Nov, 10:11 amBiocon Ltd - 532523 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011bse
12 Nov, 03:17 pmBiocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcomebse
12 Nov, 03:07 pmBiocon Limited has informed the Exchange about Link of Recordingnse
12 Nov, 08:36 amBiocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Investor Presentationbse
12 Nov, 08:25 amBiocon Limited has informed the Exchange about Investor Presentationnse
11 Nov, 08:58 pmBiocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Monitoring Agency Reportbse
11 Nov, 08:57 pmMonitoring Agency Report for the quarter ended on September 30, 2025nse
11 Nov, 08:54 pmBiocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Raising of Fundsbse
11 Nov, 08:51 pmBiocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
11 Nov, 08:49 pmBiocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreementsbse
11 Nov, 08:47 pmBiocon Limited has informed the Exchange regarding a press release dated November 11, 2025, titled "Biocon Q2FY26 Operating Revenue at Rs 4,296 Cr, Up 20% EBITDA at Rs 928 crore; Up 29%; PBT (before exceptional items) at Rs 183 Cr, Up 153%".nse
11 Nov, 08:42 pmBiocon Limited has informed the Exchange about issue of Securities through of Issuance of Commercial Papersnse
11 Nov, 08:39 pmBiocon Limited has informed the Exchange about Agreementsnse
11 Nov, 08:38 pmBiocon Ltd - 532523 - Outcome Of Board Meeting Held On November 11, 2025bse
11 Nov, 08:37 pmBiocon Limited has informed the Exchange about outcome of the Board Meeting-Early full redemption of Non-Convertible Debenturesnse
11 Nov, 08:34 pmBiocon Limited has informed the Exchange regarding Outcome of Board Meeting held on November 11, 2025.nse
11 Nov, 08:29 pmBiocon Ltd - 532523 - Financial Results For Quarter And Half Year Ended 30 September, 2025bse
11 Nov, 08:28 pmBiocon Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.nse
08 Nov, 06:00 pmBiocon Limited has informed the Exchange about Notification to Stock Exchangense
06 Nov, 05:42 pmBiocon Ltd - 532523 - Update on board meetingbse
30 Oct, 08:39 pmBiocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Credit Ratingbse
30 Oct, 08:37 pmBiocon Limited has informed the Exchange about Credit Ratingnse
30 Oct, 03:47 pmBiocon Limited has informed the Exchange regarding 'Intimation of change in status and name of step-down subsidiary of the Company'.nse
23 Oct, 06:34 pmBiocon Limited has informed the Exchange about change in name of step-down subsidiaries of the Companynse
23 Oct, 08:13 amBiocon Limited has informed the Exchange regarding a press release dated October 23, 2025, titled "Biocon Biologics Receives Health Canada Approval for Yesintek and Yesintek I.V. (ustekinumab), a Biosimilar to Stelara®".nse
16 Oct, 03:50 pmBiocon Limited has informed the Exchange regarding a press release dated October 16, 2025, titled "Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options".nse
11 Oct, 08:43 pmBiocon Limited has informed the Exchange about Company Statementnse
09 Oct, 01:19 pmBiocon Ltd - 532523 - Submission Of Copy Of Biocon India Limited Employees Welfare Trust Amendment Deedbse
09 Oct, 01:16 pmBiocon Limited has informed the Exchange about General Updatesnse
07 Oct, 08:05 amBiocon Limited has informed the Exchange about Notification to Stock Exchangesnse
06 Oct, 07:54 pmBiocon Ltd - 532523 - Board Meeting Intimation for Intimation Of The Date Of Board Meetingbse
01 Oct, 08:10 pmBiocon Limited has informed the Exchange regarding Outcome of Board Meeting held on October 01, 2025.nse
01 Oct, 08:09 pmBiocon Ltd - 532523 - Board Meeting Outcome for Early Redemption Of Ncdsbse
01 Oct, 09:01 amBiocon Limited has informed the Exchange regarding a press release dated October 01, 2025, titled "Biocon Biologics Secures U.S. Market Entry Date for Bosaya and Aukelso , Denosumab Biosimilars".nse
01 Oct, 08:59 amBiocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
28 Sept, 11:27 pmBiocon Ltd - 532523 - Board Meeting Intimation for Proposed Early Redemption Of Unlisted, Secured, Rated, Redeemable, Non-Convertible Debentures (Ncds).bse
25 Sept, 05:23 pmBiocon Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Companynse
25 Sept, 05:15 pmBiocon Ltd - 532523 - Announcement Under Regulation 30 - Receipt Of Show Cause Noticebse